Search results for: default.asp
U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms
Original Source Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5…
Read MoreEcosystem Partners
ECOSYSTEM PARTNERS BUSINESS SERVICES – ACCELERATORS* 20Fathoms ACRE AgTech Accelerator EMU Office of Tech Transfer Endeavor Detroit Entrepreneurs Organization Detroit Henry Ford Innovations Inforum Michigan Business Innovation Association Michigan Economic Development Corporation Michigan Life Science and Innovation Center MSU Conquer Accelerator MSU Innovation Center MSU Technologies MTU Office of Innovation and Commercialization NextEnergy UM Fast…
Read MoreAdvocacy
ADVOCACY MichBio advocates tirelessly for public policy that drives the growth of Michigan’s biosciences industry across a variety of market sectors. As our member companies seek to develop and manufacture sustainable, bio-based food, energy and industrial products, as well as life-changing medical devices, diagnostics, and medicines for the global consumption, MichBio assists their technology innovation…
Read MoreAbout Us
ABOUT US OUR MISSION For over 25 years MichBio has been driving bio-industry growth in Michigan by providing access to resources and information critical to success, advocating for policy decisions that support the long-term viability of the life sciences, and connecting the people, companies, and ideas necessary to create the next generation of bio-innovation. OUR…
Read More